Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Scaling Lentiviral Vector Production for Autologous CAR-T Therapies

PROVEN INTELLIGENCE IN CLINICAL-GRADE LENTIVIRAL VECTOR MANUFACTURING.

Programmatic Asset

CELL & GENE | RNA | BIOLOGICS

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Executive Summary

Scaling lentiviral (LV) vector production for autologous CAR-T therapies presents distinct challenges compared to batch-based manufacturing for allogeneic products. The process demands extreme consistency, robust analytical characterization, and a scalable platform that can support patient-specific lot production under GxP conditions. Franklin Biolabs provides tailored process development and manufacturing solutions that convert research-grade protocols into optimized, scalable systems ready for IND submission, leveraging a deep understanding of viral vector biology to minimize clinical risk.

Frequently Asked Questions

What are the primary CMC challenges when scaling lentiviral vectors for autologous CAR-T therapies?

The key CMC hurdles involve ensuring lot-to-lot consistency when each batch is intended for an individual patient. This requires developing a robust, locked-down manufacturing process, establishing stringent in-process controls, and implementing a comprehensive suite of release assays to verify vector identity, purity, potency, and safety for every production run.

How does Franklin Biolabs ensure consistency and potency for patient-specific CAR-T manufacturing lots?

We establish a standardized production platform using scalable suspension culture systems and optimized transfection parameters. Potency is confirmed using phase-appropriate, qualified cell-based assays that measure the vector’s ability to transduce the target cells and drive transgene expression, ensuring functional performance is consistent across all lots.

What is a realistic timeline for moving from a research-grade lentiviral vector to a process ready for IND-enabling studies?

A typical program timeline to achieve an IND-ready process is between 18-24 months. This encompasses process development and optimization, scale-up confirmation runs, engineering runs, and the analytical assay development required to support GxP-compliant vector release. This timeline reflects the track record of our core scientific team, which has maintained a 100% successful IND rate since 2019, even as Franklin Biolabs formally launched as a new entity in 2024.

Transitioning Lentiviral Production from Research to Clinical Application

The production of lentiviral vectors for autologous CAR-T cell therapies requires a manufacturing strategy fundamentally centered on reproducibility and analytical precision. Unlike large-batch production, the autologous model necessitates a process that can be executed consistently at a smaller scale for numerous individual patient lots. This requires moving beyond standard laboratory protocols to a well-defined, scalable, and GxP-compliant manufacturing system.

Our approach focuses on early-stage process development to establish a robust foundation for clinical manufacturing. This includes:

  • Platform Adaptation: Migrating from adherent cell culture systems, common in academic and research settings, to qualified suspension-based platforms. Suspension cultures offer superior scalability and process control, which are necessary for meeting clinical demand.

  • Parameter Optimization: Systematically defining key process parameters, including plasmid DNA ratios, transfection reagents, and cell density, to maximize functional vector titer while ensuring product quality.

  • Downstream Purification: Developing a purification train that effectively removes process-related impurities such as host cell proteins, host cell DNA, and residual plasmid DNA. A highly pure vector product is directly linked to the safety profile of the final cell therapy.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

The Role of Comprehensive Analytical Characterization

A scalable manufacturing process is only as good as the analytical methods used to characterize the vector. For LV vectors used in ex vivo cell transduction, a full suite of qualified assays is needed to ensure each batch meets specifications for identity, quantity, purity, and potency.

A robust analytical package is therefore essential for defining the critical quality attributes (CQAs) that ensure lot-to-lot consistency and link the manufacturing process to the final product’s safety and efficacy profile.

Decades of experience developing viral vectors, including adenoviral platforms, have provided key insights into managing vector biology and potential immunogenicity (PMID: 17579582, 16356525). While LV vectors for CAR-T are used ex vivo, these principles of rigorous purification and characterization are directly applicable. Minimizing residual vector components reduces the risk of unintended immune activation when the modified T-cells are infused into the patient.

Our >100,000 sq ft of specialized laboratory and housing facilities provide the infrastructure to execute these complex analytical and manufacturing workflows. This integrated environment supports the entire development lifecycle, from vector production to the execution of IND-enabling studies.

While this page focuses on lentiviral vectors, our expertise extends to other platforms. Our team has deep experience in process development for other next-generation therapies, which you can read about on our page for Large-Scale AAV Manufacturing and Process Development.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities